Back
 JCT  Vol.2 No.3 , August 2011
PrimavistTM in the Diagnosis of Oxaliplatin Induced Sinusoidal Obstruction: a Case Report
Abstract: This is a case report of a patient who underwent Oxaliplatin based neo-adjuvant chemotherapy for colorectal liver metastases, and subsequently developed sinusoidal obstruction, which was detected by Primavist enhanced MRI scan.
Cite this paper: nullM. Khan, T. Blakeborough, N. Tiffin and A. Al-Mukhtar, "PrimavistTM in the Diagnosis of Oxaliplatin Induced Sinusoidal Obstruction: a Case Report," Journal of Cancer Therapy, Vol. 2 No. 3, 2011, pp. 381-383. doi: 10.4236/jct.2011.23052.
References

[1]   L. Rubbia-Brandt, G. Y. Lauwers, H. Wang, P. E. Majno, K. Tanabe, A. X. Zhu, C. Brezault, O. Soubrane, E. K. Abdalla, J. N. Vauthey, G. Mentha and B. Terris, “Sinusoidal Obstruction Syndrome and Nodular Regenerative Hyperplasia Are Frequent Oxaliplatin Associated Liver Lesions and Partially Prevented by Bevacizumab in Patients with Hepatic Colorectal Metastasis,” Histopathology, 2010, Vol. 56, No. 4, pp. 430-439. doi:10.1111/j.1365-2559.2010.03511.x

[2]   O. Soubrane, A. Brouquet, S. Zalinski, B. Terris, C. Brezault, V. Mallet, F. Goldwasser and O. Scatton, “Predicting High Grade Lesions of Sinusoidal Obstruction Syndrome Related to Oxaliplatin-Based Chemotherapy for Colorectal Liver Metastases: Correlation with Post-Hepatectomy Outcome,” Annals of Surgery, Vol. 251, No. 3, 2010, pp. 454-460. doi:10.1097/SLA.0b013e3181c79403

[3]   R. Arotcarena, V. Cales, P. Berthelemy, Y. Parent, M. Malet, F. Etcharry, S. Ferrari and A. Pariente, “Severe Sinusoidal Lesions: A Serious and Overlooked Complication of Oxaliplatin-Containing Chemotherapy?” Gastroenterologie Clinique et Biologique, Vol. 30, No. 11, 2006, pp. 1313-1316. doi:10.1016/S0399-8320(06)73542-4

[4]   S. E. Rha, M. G. Lee, Y. S. Lee, G. H. Kang, H. K. Ha, P. N. Kim and Y. H. Auh, “Nodular Regenerative Hyperplasia of the Liver in Budd-Chiari Syndrome: CT and MR Features,” Abdominal Imaging, Vol. 25, No. 3, 2000, pp. 255-258. doi:10.1007/s002610000027

[5]   M. J. Overman, D. M. Maru, C. Charnsangavej, E. M. Loyer, H. Wang, P. Pathak, C. Eng, P. M. Hoff, J. N. Vauthey, R. A. Wolff and S. Kopetz, “Oxaliplatin Mediated Increase in Spleen Size as a Biomarker for the Development of Hepatic Sinusoidal Injury,” Journal of Clinical Oncology, Vol. 28, No. 15, 2010, pp. 2549-2555. doi:10.1200/JCO.2009.27.5701

[6]   E. Oki, Y. Kakeji, A. Taketomi, Y. Yamashita, K. Ohgaki, N. Harada, T. Iguchi, K. Shibahara, N. Sadanaga, M. Morita and Y. Maehara, “Transient Elastography for the Prediction of Oxaliplatin-Associated Liver Injury in Colon Cancer Patients: A Preliminary Analysis,” Journal of Gastrointest Cancer, Vol. 39, No. 1-4, 2008, pp. 82-85. doi.org/10.1007/s12029-009-9063-1

[7]   O. Dohr, R. Hofmeister, M. Treher and H. Schweinfurth, “Preclinical Safety Evaluation of Gd-EOB-DTPA (Pri- movist),” Investigative Radiololgy, Vol. 42, No. 12, 2007, pp. 830-841. doi.org/10.1097/RLI.0b013e318137a471

 
 
Top